HIF1A and lung carcinoma: Panaxynol treatment also significantly inhibits the interaction between HIF-1α and Hsp90, reducing HIF-1α protein levels and VEGF mRNA levels in a dose-dependent manner, further supporting its anti-lung cancer effects (Lee et al., 2018; Le et al., 2018).